NEW YORK, Feb. 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
In recent years, the number of protein-based pharmaceuticals reaching the marketplace has increased exponentially. The clinical application of these drugs is limited by a lack of desirable attributes for adequate absorption or distribution. It therefore becomes critical to formulate these drugs into safe, stable and efficacious delivery systems. Because these drugs face formidable enzymatic and penetration barriers when administered orally, peptide and protein drugs continue to be developed almost exclusively for parenteral administration. These combination drug-device products, where the drug and device are clinically tested and approved as a single product entity, are becoming one of the fastest new drug categories. On a unit basis, in spite of their higher cost protein drugs are growing in excess of fifteen percent annually. The growth of protein drug products is having a significant effect on the way drugs and devices are developed. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies.
To order this report:: Therapeutic Proteins to 2014
Copyright©2010 PR Newswire.
All rights reserved